Augustine Lawlor

Catalyst Bioscience, Inc. develops and markets catalytic biopharmaceutical products. Its technology consists of methods to identify proteases with tailor-made specificity or improved pharmacological properties. The company was founded by Charles Craik, Sandra Waugh Ruggles and Christopher Thanos in 2003 and is headquartered in South San Francisco, CA.

Adheron Therapeutics, Inc. discovers and develops therapeutic drugs. The firm offers Cadherin-11 antagonists for the treatment of rheumatoid arthritis and fibrotic diseases including pulmonary fibrosis and skin fibrosis. The company was founded by David Lee, Michael B. Brenner, and David L. Castaldi in 2006 and is headquartered in Berkeley, CA.

Asterand Biosciences, Inc. provided stem cell research products. It offered proprietary reagents and tools developed by stem cell scientists. The firm's products included small molecules for pluripotency, self-renewal and differentiation, viral-delivered transcription factors, matrices, cell lines, cytokines, antibodies and transfection reagents. The company was founded by Ian W. Ratcliffe, Stephen M. Chang and Sheng Ding in 2006 and headquartered in Detroit, MI.

Mosaic Biosciences, Inc. provides commercial research and development services. It conducts research on synthetic materials that support native tissue regeneration. The firm's solutions are designed for application in wound healing, bone regeneration, cartilage repair, stem cell therapy, and dermal fillers. The company was founded by Martin Stanton, Chris Bowman, Kristi S. Anseth and Peter Mariner in 2009 and is headquartered in Boulder, CO.

Tensha Therapeutics, Inc. develops small molecule bromodomain inhibitors. The firm’s product is used to treat cancer and other serious disorders. The company was founded by James Bradner in 2011 and is headquartered in Cambridge, MA.

GITR, Inc. develops immune modulatory responses to treat cancer. The company was founded in 2011 and is headquartered in Cambridge, MA.

Layerbio, Inc. develops bio erodible sustained-release technology for use in standard intraocular lens in cataract surgery. The private company is based in Lexington, MA. The company was founded in 2013 by Kenneth J. Mandell, Paula Hammond. Kenneth J. Mandell has been the CEO since 2013.

HealthCare Ventures LLC (HealthCare Ventures) is a venture capital firm founded in 1985 by Harold R. Werner. The firm is headquartered in Cambridge, Massachusetts.

Phase Forward, Inc. developed e-process software solutions for accelerating global pharmaceutical development. The company was founded by Paul A. Bleicher and Augustine in 1997 and was headquartered in Waltham, MA.

Part of Amphastar Pharmaceuticals, Inc., Armstrong Pharmaceuticals, Inc. is a private company that manufactures aerosol pharmaceutical products. The company is based in New Canaan, CT.

Part of Sanofi, BioSurface Technology, Inc. is a commercial biotechnical research company. The private company is based in Cambridge, MA. The company was founded by David L. Castaldi, Ben R. Bronstein. BioSurface Technology was acquired by Genzyme Corp., part of Sanofi from April 08, 2011 on December 16, 1994.

Upstate Group LLC develops cell signaling products, technology platforms and services. It provides researchers at pharmaceutical and biotechnology companies, universities and government agencies with advanced tools to accelerate life science research and drug discovery. Upstate Group is a subsidiary of Serologicals Corp. The company was founded in 1988 and is headquartered in Charlottesville, VA.

PathoGenetix, Inc. operates as a commercial-stage developer of an automated system for rapid bacterial identification from complex samples. Its Genome Sequence Scanning technology isolates and analyzes DNA from an enriched biological sample, without the need for a cultured isolate. The firm specializes in food safety, industrial microbiology, and clinical diagnostics and research. The company was founded in 1997 and is headquartered in Watertown, MA.

Promedior, Inc. is a clinical-stage immunotherapy company, which engages in the development of targeted therapeutics to treat fibrotic diseases. Its proprietary therapeutic platform is based upon Pentraxin-2, an endogenous human protein that plays an important role in regulating the response to fibrosis. The company was founded by Gomer H. Richard, Lawrence M. Kauvar, and Darrell Pilling in April 2006 and is headquartered in Lexington, MA.

VaxInnate Corp. develops novel, proprietary vaccines for infectious diseases. It engages in the development and production of vaccines for pandemic and seasonal influenza diseases. The firm's products include Flagellin.HuHA and flagellin.AvHA, which are fusion proteins linking a potent immune stimulator, the bacterial protein flagellin, with immunoprotective domain of viral hemagglutinin. The company was founded by Ruslan Medzhitov, Michael I. Sherman and Richard Flavell in 2002 and is headquartered in Cranbury, NJ.

Arresto Biosciences, Inc. is a biotech company that develops medicines to treat cancer and fibrotic diseases by targeting extracellular matrix proteins. The company was founded by Amato Giaccia, Michael T. Longaker and Geoffrey C. Gurtner in 2007 and is headquartered in Palo Alto, California.

Anexon, Inc. develops therapeutics for cardiovascular diseases. The firm develops an alternatively spliced variant of brain natriuretic peptide, ANX-042, for the treatment of patients with chronic heart failure and kidney dysfunction. The company was founded in 2006 by Robert D. Simari and is headquartered in Cambridge, MA.

DNA Electronics, Inc. develops medical diagnostic devices. It also develops novel diagnostic systems for the rapid isolation of rare cell types including bacterial and fungal pathogens, directly from blood and other matrices. The company was founded by Waneta C. Tuttle in 2007 and is headquartered in Albuquerque, NM.

Cardiovascular Systems, Inc. is a medical device company, which engages in the development and commercialization of solutions for treating vascular and coronary disease. It offers orbital atherectomy systems for both peripheral and coronary commercial applications. The company was founded in 1989 and is headquartered in St. Paul, MN.

Cleveland HeartLab, Inc. operates as a holding and clinical reference laboratory company. It focuses on novel molecular biomarker technologies and the creation of proprietary diagnostic tests. The company was founded by Jake Orville and Marc S. Penn in 2009 and is headquartered in Cleveland, OH.

TetraLogic Research & Development Corp. develops SHP-141 topical HDAC inhibitor clinical development for cutaneous T cell lymphoma. Its currently conducting a randomized, double-blind, placebo controlled, phase 1b study, to evaluate the safety and tolerability of SHP-141 in patients with stage 1A, 1B or 2A CTCL. The company was founded by James E. Bradner and Ralph Mazitschek in 2008 and is headquartered in Cambridge, MA.

Viriom Ltd. operates as a biotech company which develops novel therapies for life threatening infections such as HIV and HBV. The company was founded in 2009 and is headquartered in Khimki, Russia.

Catalyst Biosciences, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the development of novel medicines to address serious medical conditions. The company was founded on March 7, 1997 and is headquartered in South San Francisco, CA.

Part of HealthCare Ventures LLC, Healthcare Strategic Partners, LLC is an American company that provides healthcare services.

Teal Ventures Management LLC (Teal Ventures) is a venture capital firm founded by Nikolay Savchuk, Ron Demuth, and Eddie Rodriguez in 2018. The firm Headquartered in San Diego, California.

Viriom, Inc. is a biotechnology company based in San Diego, CA. The company focuses on developing innovative therapies for infectious diseases, including HIV and COVID-19. Viriom's mission is to improve the lives of patients by providing effective and accessible treatments. Iain David Dukes has been the CEO of the company since 2019, leading the team in their efforts to advance the development of their pipeline and bring new therapies to market.

Celyn Therapeutics, Inc. develops molecule products for clinical use with a focus on targeting cancer.